Literature DB >> 10568577

Reporting bias in retrospective ascertainment of drug-induced embryopathy.

B Bar-Oz, M E Moretti, G Mareels, T Van Tittelboom, G Koren.   

Abstract

The rate of congenital malformations after first-trimester exposure to itraconazole was four times higher when ascertained retrospectively than prospectively (13.0 vs 3.2%, p=0.006). Reporting bias in retrospective studies should be acknowledged in interpretation of such data.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10568577     DOI： 10.1016/s0140-6736(99)04411-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  13 in total

1.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.

Authors:  Katharina R Beck; Murielle Bächler; Anna Vuorinen; Sandra Wagner; Muhammad Akram; Ulrich Griesser; Veronika Temml; Petra Klusonova; Hideaki Yamaguchi; Daniela Schuster; Alex Odermatt
Journal:  Biochem Pharmacol       Date:  2017-01-25       Impact factor: 5.858

Review 3.  Statins and pregnancy: between supposed risks and theoretical benefits.

Authors:  Edouard Lecarpentier; Olivier Morel; Thierry Fournier; Elisabeth Elefant; Pascale Chavatte-Palmer; Vassilis Tsatsaris
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

Review 4.  Pregnancy and renal failure: the case for application of dosage guidelines.

Authors:  F Keller; M Griesshammer; U Häussler; W Paulus; A Schwarz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Safety of oseltamivir in pregnancy: a review of preclinical and clinical data.

Authors:  Barbara Donner; Viswanathan Niranjan; Gerhard Hoffmann
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

6.  Parenthood and immunomodulation in patients with multiple sclerosis.

Authors:  Kerstin Hellwig; Aiden Haghikia; Ralf Gold
Journal:  J Neurol       Date:  2009-11-21       Impact factor: 4.849

7.  First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy.

Authors:  Marco De Santis; Elena Di Gianantonio; Elena Cesari; Guido Ambrosini; Gianluca Straface; Maurizio Clementi
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Methodological approaches to evaluate teratogenic risk using birth defect registries: advantages and disadvantages.

Authors:  Fernando A Poletta; Jorge S López Camelo; Juan A Gili; Emmanuele Leoncini; Eduardo E Castilla; Pierpaolo Mastroiacovo
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

Review 9.  Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance.

Authors:  Elizabeth Brunner; Deborah M Falk; Meghan Jones; Debashish K Dey; Chetan Chinmaya Shatapathy
Journal:  BMC Pharmacol Toxicol       Date:  2013-08-01       Impact factor: 2.483

10.  Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy.

Authors:  Patricia Schlagenhauf; William A Blumentals; Pia Suter; Loredana Regep; Gabriel Vital-Durand; Martin T Schaerer; Margarita Suarez Boutros; Hans-Georg Rhein; Miriam Adamcova
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.